DE69838334D1 - Kdr, ein menschlicher tyrosin kinase rezeptor - Google Patents

Kdr, ein menschlicher tyrosin kinase rezeptor

Info

Publication number
DE69838334D1
DE69838334D1 DE69838334T DE69838334T DE69838334D1 DE 69838334 D1 DE69838334 D1 DE 69838334D1 DE 69838334 T DE69838334 T DE 69838334T DE 69838334 T DE69838334 T DE 69838334T DE 69838334 D1 DE69838334 D1 DE 69838334D1
Authority
DE
Germany
Prior art keywords
kdr
tyrosine kinase
kinase receptor
human
human tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69838334T
Other languages
English (en)
Other versions
DE69838334T2 (de
Inventor
Richard L Kendall
Kenneth A Thomas
Xianzhi Mao
Andrew Tebben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21968566&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69838334(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE69838334D1 publication Critical patent/DE69838334D1/de
Publication of DE69838334T2 publication Critical patent/DE69838334T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69838334T 1997-06-18 1998-06-17 Kdr, ein menschlicher tyrosin kinase rezeptor Revoked DE69838334T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5096297P 1997-06-18 1997-06-18
US50962P 1997-06-18
PCT/US1998/012569 WO1998058053A1 (en) 1997-06-18 1998-06-17 Human receptor tyrosine kinase, kdr

Publications (2)

Publication Number Publication Date
DE69838334D1 true DE69838334D1 (de) 2007-10-11
DE69838334T2 DE69838334T2 (de) 2008-06-12

Family

ID=21968566

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69838334T Revoked DE69838334T2 (de) 1997-06-18 1998-06-17 Kdr, ein menschlicher tyrosin kinase rezeptor

Country Status (8)

Country Link
US (4) US6204011B1 (de)
EP (1) EP1009814B1 (de)
JP (1) JP4405597B2 (de)
AT (1) ATE371727T1 (de)
CA (1) CA2293723A1 (de)
DE (1) DE69838334T2 (de)
ES (1) ES2292204T3 (de)
WO (1) WO1998058053A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
AU1633999A (en) * 1997-12-09 1999-06-28 Children's Medical Center Corporation Soluble inhibitors of vascular endothelial growth factor and use thereof
AU2469299A (en) * 1998-01-23 1999-08-09 Cornell Research Foundation Inc. Purified populations of stem cells
IL142583A0 (en) * 1998-11-06 2002-03-10 Basf Ag Inhibition of the formation of vascular hyperpermeability
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
CA2411072A1 (en) 2000-06-07 2001-12-13 Ortho-Mcneil Pharmaceutical, Inc. Method to detect modulators of vegf kinase domain
EP1515707A4 (de) * 2001-06-20 2005-10-19 Imclone Systems Inc Verfahren zur behandlung von atherosklerose und anderer entzündlicher erkrankungen
US6734017B2 (en) * 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
EP1587944A4 (de) 2002-03-01 2007-03-21 Dyax Corp Kdr und vegf/kdr-bindende peptide und ihre diagnostische und therapeutische veranwendung bei der diagnose und therapie
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
DK1916001T3 (da) * 2002-03-04 2011-07-18 Imclone Llc KDR-specifikke humane antistoffer og anvendelser deraf
GB0206072D0 (en) * 2002-03-15 2002-04-24 Astrazeneca Ab Epitope
EP2270042B1 (de) 2002-09-12 2015-01-14 Oncotherapy Science, Inc. KDR-Peptide und diese enthaltende Impfstoffe
US20060057694A1 (en) * 2003-01-29 2006-03-16 Thomas Kenneth A Jr Rat receptor tyrosine knase, kdr
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
EP1626988A2 (de) * 2003-05-16 2006-02-22 Receptor Biologix, Inc. Intron fusionproteinen und methoden deren identifizierung und verwendung
WO2005046602A2 (en) * 2003-11-10 2005-05-26 Greenville Hospital System Vegf receptor antagonists
CA2565974A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
ATE470454T1 (de) * 2004-09-13 2010-06-15 Genzyme Corp Multimere konstrukte
WO2006042002A2 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
JP3992077B2 (ja) * 2005-05-11 2007-10-17 株式会社村田製作所 アンテナ構造およびそれを備えた無線通信機
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
JP2010509598A (ja) * 2006-11-13 2010-03-25 ライフ テクノロジーズ コーポレーション 前立腺癌バイオマーカーを検出するための方法およびキット
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
JP2013539962A (ja) 2010-07-09 2013-10-31 ジェネンテック， インコーポレイテッド 抗ニューロピリン抗体及び使用方法
WO2012019128A1 (en) 2010-08-06 2012-02-09 Genzyme Corporation Vegf antagonist compositions and uses thereof
WO2013074814A2 (en) * 2011-11-15 2013-05-23 University Of Utah Research Fourdation Morpholinos, morpholino upregulating, and associated methods
WO2013159051A1 (en) 2012-04-19 2013-10-24 University Of Utah Research Foundation Morpholino-mediated increase in soluble flt-1 expression results in decreased ocular and tumor neovascularization

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
SG49753A1 (en) * 1991-02-22 1998-06-15 American Cyanamid Co Identification of a novel human receptor tyrosine kinase gene
CA2064331C (en) 1991-03-28 2003-02-18 Marvin L. Bayne Vascular endothelial cell growth factor c subunit
US5861301A (en) * 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
CN1173991C (zh) * 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis

Also Published As

Publication number Publication date
DE69838334T2 (de) 2008-06-12
CA2293723A1 (en) 1998-12-23
US20030032160A1 (en) 2003-02-13
JP4405597B2 (ja) 2010-01-27
EP1009814A1 (de) 2000-06-21
WO1998058053A9 (en) 1999-04-08
EP1009814A4 (de) 2001-12-12
US6841382B2 (en) 2005-01-11
US6204011B1 (en) 2001-03-20
US6359115B1 (en) 2002-03-19
EP1009814B1 (de) 2007-08-29
US20030055239A1 (en) 2003-03-20
WO1998058053A1 (en) 1998-12-23
ATE371727T1 (de) 2007-09-15
JP2002507119A (ja) 2002-03-05
US6841367B2 (en) 2005-01-11
ES2292204T3 (es) 2008-03-01

Similar Documents

Publication Publication Date Title
DE69838334D1 (de) Kdr, ein menschlicher tyrosin kinase rezeptor
WO1999055868A3 (en) Fizz proteins
DE69834027D1 (de) Tumor-nekrose-faktor rezeptor 5
EP1464706A3 (de) HEK5, HEK7, HEK8, HEK11, EPH-ähnliche Protein-Tyrosinkinase-Rezeptoren
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DK1129190T3 (da) Human TSLP DNA og polypeptider
DK0970213T3 (da) Dödsdomæneholdig receptor
ATE541931T1 (de) Il-17-homologe polypeptide und ihre therapeutische verwendung
DK0961831T3 (da) Humant alfa-endokin
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
DE69728897D1 (de) Saeugetierchemokine
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
WO1998027932A3 (en) Cerebellum and embryo specific protein
WO2002012475A3 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof
DE60124380D1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
WO2004070004A3 (en) Rat receptor tyrosine kinase, kdr
NZ510812A (en) Novel peptides
AU4956901A (en) Novel human 7tm proteins and polynucleotides encoding the same
WO2001057086A3 (en) Novel human g protein coupled receptor proteins and polynucleotides encoding the same
ATE492640T1 (de) Loslösendes protein 5 - ucp5
WO2002077190A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002016435A3 (en) Human 7tm proteins and polynucleotides encoding the same
WO2002061062A3 (en) Human protein kinase n-like polypeptide and uses thereof
ATE476194T1 (de) Ein mitglied der menschlichen proteinkinasefamilie, und verwendungen dafür
WO2002000709A3 (en) Cerebellin homologous polypeptides and therapeutic uses thereof

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation